ArticleCase reports in hematology2026
Celiac Disease Emerging After ASCT in Multiple Myeloma: A Rare Diagnostic Intersection and Literature Review.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autologous stem cell transplantation (ASCT) is a standard component of therapy for eligible patients with multiple myeloma. Persistent gastrointestinal symptoms after ASCT are commonly attributed to infection, medication-related toxicity, or disease relapse, whereas autoimmune enteropathies such as celiac disease are rarely considered. Case Presentation: We report a 53-year-old woman with lambda light-chain multiple myeloma who achieved complete remission after bortezomib, lenalidomide, and dexamethasone induction followed by ASCT and lenalidomide maintenance. Four months after transplantation, she developed persistent diarrhea and a 4-kg unintentional weight loss. Infectious investigations were negative, and imaging and bone marrow assessment showed no evidence of myeloma relapse. Upper gastrointestinal endoscopy demonstrated duodenal villous atrophy, and biopsy findings were consistent with Marsh 3A celiac disease. Serum antitissue transglutaminase IgA was markedly elevated at > 123 U/mL. A strict gluten-free diet resulted in complete resolution of diarrhea within 2 weeks and a subsequent decline in celiac serologic markers. Lenalidomide-associated diarrhea or enteropathy was considered but could not be definitively excluded because treatment withdrawal and rechallenge were not performed. In addition, pre-ASCT celiac serology and HLA-DQ2/DQ8 typing were unavailable. Conclusion: This case highlights celiac disease as a rare but clinically important cause of persistent diarrhea after ASCT. Immune reconstitution following transplantation may unmask previously subclinical autoimmune disease. Clinicians should maintain a broad differential diagnosis for posttransplant gastrointestinal symptoms, as early recognition and appropriate dietary intervention can lead to rapid symptom resolution and prevent unnecessary treatment interruption or morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.